dr. melnick on epigenetic diversity and clinical outcomes in dlbcl
Published 10 years ago • 136 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
3:38
dr. melnick on epigenetic biomarkers in types of lymphoma
-
2:04
dr. melnick on targeting ezh2 in dlbcl
-
1:28
dr. ari melnick on malt1 as a potential target in dlbcl
-
3:19
dr. ari m. melnick on biomarkers in lymphoma
-
2:14
dr. melnick on ezh2 as a potential target in diffuse large b cell lymphoma
-
1:16
dr. melnick discusses the epigenetic basis of b-cell lymphomas
-
9:00
dlbcl: treatment and phenotypes
-
1:09
dr. melnick on emerging targets in lymphoma
-
22:33
epigenetic therapy for lymphoma: from the laboratory to the clinic
-
1:41
dr. melnick on targeting malt1 in abc--dlbcl
-
7:18
precision epigenetic therapy for b-cell lymphoma
-
2:27
dr. melnick discusses the future of chemotherapy in lymphomas
-
1:35
dr. dogan on updated who classifications in dlbcl
-
0:59
dr. nowakowski on the rationale of the engine trial in dlbcl
-
2:35
association of interim pet2 response with outcomes in patients with dlbcl
-
1:09
areas of unmet need for dlbcl: primary refractory disease and double-hit lymphoma
-
3:00
what is diffuse large b-cell lymphoma (dlbcl)?
-
6:37
l-mind trial in relapsed/refractory dlbcl
-
2:27
elucidating the genetic and molecular basis of dlbcl